Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms

Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield...

Full description

Bibliographic Details
Main Authors: Claudia Pivonello, Roberta Patalano, Mariarosaria Negri, Rosa Pirchio, Annamaria Colao, Rosario Pivonello, Renata Simona Auriemma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Endocrinology
Subjects:
dopamine
dopamine agonist
pituitary tumors
cabergoline
prolactinomas
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full

Similar Items